Lack of leukocyte migration inhibition by hepatitis B surface antigen in hepatocellular carcinoma patients
- PMID: 94850
Lack of leukocyte migration inhibition by hepatitis B surface antigen in hepatocellular carcinoma patients
Abstract
Soluble part of hepatocellular carcinoma (HCC) tissue extracts with or without hepatitis B surface antigen (HBsAg) was tested against leukocytes of 13 histologically confirmed HCC patients. Inhibition of leukocyte migration was observed in 9 out of 13 cases when tested by soluble HCC extract containing HBsAg, while inhibition of lukocyte migration was observed in 8 out of 13 cases when tested by solublp greater than 0.05, by Fisher's exact test). In the meantime, soluble HCC extract with or without HBsAg did not significantly cause inhibition of leukocyte migration in 12 non-HCC patients. Therefore, it is concluded that inhibition of leukocyte migration in HCC patients is caused by the tumor-associated antigen, not caused by HBsAg.
Similar articles
-
Inhibition of leukocyte migration by tumor-associated antigen in soluble extracts of human hepatoma.Cancer Res. 1977 Mar;37(3):918-21. Cancer Res. 1977. PMID: 189919
-
Purification of soluble hepatocellular carcinoma extracts.Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi. 1979 Sep;12(3):81-5. Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi. 1979. PMID: 232674
-
Hepatitis B surface antigen and alpha-1-fetoprotein in hepatoma. Reports of 157 cases.J Med Assoc Thai. 1983 Nov;66(11):696-9. J Med Assoc Thai. 1983. PMID: 6200559 No abstract available.
-
[Hepatocellular carcinoma, hepatitis B virus and the immune system].Schweiz Med Wochenschr. 1986 Aug 23;116(34):1133-45. Schweiz Med Wochenschr. 1986. PMID: 3020684 Review. German.
-
Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer.Expert Opin Biol Ther. 2008 Mar;8(3):325-36. doi: 10.1517/14712598.8.3.325. Expert Opin Biol Ther. 2008. PMID: 18294103 Review.